Overview of current clinical registries

Oncology, radiotherapy

 Directory of registries

BIOMARKERY PANKREAS

Evaluation of efficacy of new spectroscopic biomarkers for the detection of early-stage pancreatic cancer.

Breast

Clinical registry of breast cancer patients who have been treated with trastuzumab (Herceptin®), lapatinib (Tyverb®), bevacizumab (Avastin®) and/or everolimus (Afinitor®).

CAMELIA – Chronic MyEloid LeukaemIA

International clinical registry of patients with chronic myeloid leukaemia.

Cervix.cz – Cervical Cancer Screening Programme in the Czech Republic

System of informational support for the Cervical Cancer Screening Programme in the Czech Republic.

CLLEAR

Clinical registry of patients with chronic lymphocytic leukaemia (CLL).

Corect

Clinical registry of colorectal cancer (CRC) patients who have been treated with cetuximab (Erbitux®), bevacizumab (Avastin®) and/or panitumumab (Vectibix®).

CyRUS – Cystectomy Registry of the Czech Urological Society

Clinical registry monitoring cases of bladder cancers treated with cystectomy and consecutive treatment.

DATOOL ALL

Clinical registry of patients with acute lymphoblastic leukaemia (ALL).

DATOOL AML

Clinical registry of patients with acute myeloid leukaemia (AML).

DoIT!

Non-interventional, multicentre, retrospective and prospective study of patients with brain tumours, who have been treated in the Czech Republic according to the common clinical practice.

FIND

Clinical registry of haemato-oncological patients in which antimycotic therapy has been administered.

Infinity

Clinical registry of patients with chronic myeloid leukaemia (CML).

KELLY

Registry of EGFR mutation testing results in patients with non-small-cell lung cancer (NSCLC) in the Czech Republic.

Kolorektum.cz – Colorectal Cancer Screening Programme in the Czech Republic

System of informational support for the Colorectal Cancer Screening Programme in the Czech Republic.

Magister

Central Czech registry of morphologically examined breast cancers, with particular emphasis on the collection of data regarding the examination of HER2/neu status in the Czech population.

Mamo.cz – Breast Cancer Screening Programme in the Czech Republic

System of informational support for the Breast Cancer Screening Programme in the Czech Republic.

MDS – MyeloDysplastic Syndrome

Clinical registry of patients with myelodysplastic syndrome.

Melanom

Clinical registry of melanoma patients who have been treated with dabrafenib (Tafinlar®), ipilimumab (Yervoy®), nivolumab (Opdivo®), trametinib (Mekinist®), pembrolizumab (Keytruda®) and/or vemurafenib (Zelboraf®).

MIND

Clinical registry of patients with myeloproliferative disorders.

NERO

NERO (Nausea/Emesis Registry in Oncology) is multicentric non-interventional prospective study assessing antiemetic guidelines consistency in chemotherapy-induced nausea and vomiting (CINV) prophylaxis and the impact of CINV on the quality of life on cancer patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC).

NET – NEuroendocrine Tumours

Český registr neuroendokrinních nádorů.

NSCLC stage III

International clinical registry gathering data on the management of patients with non-small cell lung cancer (NSCLC) who were diagnosed at the clinical stage III.

OVARIA

Clinical registry of ovarian cancer patients who have been treated with bevacizumab (Avastin®) and/or olaparib (Lynparza®).

Pemetrexed

Clinical registry of pleural mesothelioma patients who have been treated with pemetrexed (Alimta®).

reGISTer

Clinical registry monitoring the epidemiology of gastrointestinal stromal tumours (GIST) as well as therapeutic approaches and treatment results in GIST patients in the Czech Republic and Slovakia.

RenIS

Clinical registry of kidney cancer patients who have been treated with bevacizumab (Avastin®), everolimus (Afinitor®), pazopanib (Votrient®), sorafenib (Nexavar®), sunitinib (Sutent®) and/or temsirolimus (Torisel®).

RESET

Clinical registry of patients suffering from sellar tumours.

Tulung

Clinical registry of non-small cell lung cancer (NSCLC) patients who have been treated with bevacizumab (Avastin®), erlotinib (Tarceva®), gefitinib (Iressa®), pemetrexed (Alimta®), afatinib (Giotrif®) and/or nintedanib (Vargatef®).